LTX-401

About Lytix Biopharma

Lytix Biopharma is pioneering a novel class of oncolytic molecule therapies designed to overcome tumor immunosuppression and enhance the efficacy of immune checkpoint inhibitors. The company's lead asset, ruxotemitide (LTX-315), is in Phase 2 development for neoadjuvant melanoma and has shown promising activity in other skin cancers. With a focused strategy on the pre-surgical setting and a platform applicable to both superficial and deep-seated tumors, Lytix is positioning itself to address significant unmet needs in immuno-oncology. The company is actively seeking partnerships to advance its pipeline toward registrational studies.

Therapeutic Areas